The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Eli Lilly's tirzepatide leads to 50% more weight loss compared to Novo Nordisk's semaglutide in 72-week study.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...

Researchers randomly assigned people with obesity (but not type 2 diabetes) to take either Zepbound or Wegovy for 72 weeks. All received weekly injections of the highest medication dose they could ...

None had diabetes, The Associated Press reported. Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide). After 72 weeks, people taking Zepbound lost an ...